The Chongqing Key Laboratory of Molecular Oncology and Epigenetics has established three main research directions: tumor epigenetics, tumor microenvironment and translational medicine, with the core advantage of studying tumor epigenetic mechanisms. The laboratory covers an area of 1200 square meters and is equipped with advanced scientific research instruments and equipment, such as laser confocal microscope, flow cytometer, small animal in vivo fluorescence imaging and digital PCR, etc., with a total value of about 15 million RMB, which provides a strong guarantee for the smooth development of scientific research.
The laboratory has a research team with reasonable structure and excellent professional quality. There are 46 researchers, 5 professional technicians and 2 full-time managers. There are 46 researchers, 5 professional technicians and 2 full-time administrators, including 1 National Jieqing, 1 Changjiang Scholar Distinguished Professor of the Ministry of Education, and 13 provincial and ministerial level talents. The research team is organized in the form of “discipline leaders leading, research backbone support, full-time technician assistance, postgraduate students participation”, with the goal of improving the overall research water capacity of the discipline, to lead by the point, and then form a scientific research team with innovation ability. As a public platform for scientific research services, the laboratory has provided scientific research services for thousands of graduate students, with more than 80 graduate students in the laboratory every year.
Featured Platforms:
1、Tumor Epigenetics and Tumor Molecular Marker Screening Research Platform
This platform is dedicated to the in-depth analysis of the biological behavior of malignant tumors in the process of occurrence and development, specifically covering the key links of tumor cell proliferation, differentiation, metastasis and apoptosis. Through the comprehensive use of molecular biology, cell biology, gene microarray, protein microarray and other cutting-edge technologies, the platform aims to reveal the biological mechanisms of malignant tumors and search for molecular markers with significance in early diagnosis, treatment or prognosis of common malignant tumors in China. Through the organic combination of basic experimental research and clinical (diagnosis, staging and gene therapy) research, combined with the dual path of theoretical exploration and technological innovation, we strive to obtain the gene and protein profiles of markers that can be applied to the early diagnosis, clinical staging and prognosis of malignant tumors. These research results will provide powerful information and technical support for the early specific diagnosis of clinical malignant tumors and the judgment of treatment and prognosis, thus promoting the in-depth development of translational medicine in the field of oncology.
2、Tumor Microenvironmental Biology Research Mechanism Platform
This platform takes the tumor microenvironment as the entry point for research, and uses advanced technologies such as cell biology, molecular biology, bioinformatics, etc., to explore the mechanism of tumor development in depth. The research focuses on the signaling role and functional mechanisms between the tumor microenvironment and cancer cells, with a view to comprehensively elucidating the biological mechanisms of the tumor microenvironment in tumorigenesis (e.g., pro-tumorigenic and tumor growth) and development (pro-angiogenic and pro-metastatic). Through this research, we aim to provide a solid theoretical basis for molecular therapies targeting the tumor microenvironment.
3、Tumor Translational Medicine Research Platform
This platform aims to develop innovative diagnostic methods for tumor markers and screen potential anti-tumor drug targets through the comprehensive use of molecular biology, cell biology, proteomics, medicinal chemistry, pharmacology, pharmacy, diagnostics, clinical medicine and other multidisciplinary means. For both known and new targets, we use high-throughput technology and computerized virtual screening methods to screen potential inhibitory drugs and to deeply reveal the molecular mechanism of drug inhibition of tumors. On this basis, we actively carry out the research and development of new drugs and focus on the translation and application of the results, with a view to providing new effective means and drugs for the clinical treatment of tumors.
